Navigation Links
New Data Supports ConvaTec Negative Pressure Wound Therapy

SKILLMAN, N.J., Aug. 17 /PRNewswire/ -- ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, announced today the publication of new data demonstrating positive clinical results achieved with the Engenex((R)) Advanced Negative Pressure Wound Therapy (NPWT) system.

The Engenex((R)) NPWT System, utilizing low pressure (75 mm Hg) and EasyRelease(TM) dressings incorporating Bio-Dome(TM) Interface Technology, is designed to safely and effectively promote the healing of difficult wounds.

The case series study, published in the June issue of the journal Ostomy Wound Management, evaluated use of the next generation NPWT system in the management of complex surgical and traumatic wounds. Following the application of the NPWT system in a protocol of care, all three cases showed a marked progression toward wound healing, with reduced wound volume and development of healthy granulated tissue. Clinicians also observed that the dressing - developed specifically for use with the Engenex((R) )NPWT system - was well tolerated, with no tissue growth into the dressing, "little to no" disturbance of the granulation bed during dressing changes, and "little to no" bleeding or trauma on removal of the dressing.

"As our experience and these cases suggest, we believe that the Engenex NPWT System, with its low pressure profile and unique, non-adherent dressings, may represent an advance in this technology, possibly benefiting wound and patient outcomes," said author Cheryl Nease, PT, Memorial Health Center in Savannah, GA.

In December 2008, ConvaTec signed a long-term global exclusive license agreement with Boehringer Technologies to market and distribute the Engenex((R)) NPWT System incorporating Bio-Dome(TM) Interface Technology. The Engenex((R)) NPWT System is an innovative technology and engineering solution that utilizes the application of negative pressure to a wound to promote healing by creating controlled tissue strain and removing excess fluid, including wound exudate. Every aspect of the System, from the wound interface to the user interface, has been designed to attain optimal clinical outcomes as well as a simplified application and monitoring system for patient care.

"This publication is just the beginning in the development of our clinical evidence base in support of this advanced NPWT technology," said Marcus Schabacker, Chief Scientific Officer, ConvaTec. "As the researcher noted, the acceptable levels of observed pain, exudate management, minimal bleeding and wound bed disruption are important factors for clinicians managing complex wounds and for the patients they care for - and validates the excellent response we have been receiving from our initial customers."

About ConvaTec

ConvaTec is a leading developer and marketer of innovative medical technologies that have helped improve the lives of millions of people worldwide. With four key business divisions - Ostomy Care, Wound Therapeutics, Continence and Critical Care and Infusion Devices - ConvaTec products support health care professionals from the hospital to the community health setting. From its headquarters in Skillman, New Jersey, the company oversees more than 8,000 employees in over 90 countries serving consumers and their health care professionals on six continents. For more information, please visit

Engenex is a registered trademark, and EasyRelease and Bio-Dome are trademarks of Boehringer Technologies L.P.

Our world is what we make of it is a trademark of ConvaTec Inc.

(C) 2009 ConvaTec Inc.


(1) Nease C. Using low pressure, negative pressure wound therapy for wound preparation and the management of split-thickness skin grafts in three patients with complex wounds. Ostomy Wound Management 2009;55(6)32-42.


    Punnie Donohue

    Courtney Judd
    Weber Shandwick

Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Supports Efficacy of Vagus Nerve Stimulation for Treatment-Resistant Depression
2. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer
4. Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis
5. New Data from the Framingham Heart Study Supports PAT Technology to Diagnose Early Cardiovascular Disease
6. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
7. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
8. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
9. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
10. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
11. New Clinical Data Further Supports Chromium Picolinates Role in Enhancing Brain Activity in Older Adults
Post Your Comments:
(Date:6/24/2016)... June 24, 2016 ... announced the addition of the " Global Markets ... This report focuses ... an updated review, including its applications in various applications. ... market, which includes three main industries: pharmaceutical and biotechnology, ...
(Date:6/24/2016)... -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM ... sells medical devices and wearable sleep respiratory products in ... agreement with Hongyuan Supply Chain Management Co., Ltd. (hereinafter ... 2016, to develop Dehaier,s new Internet medical technology business. ... leverage Hongyuan Supply Chain,s sales platform to reach Dehaier,s ...
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
Breaking Medicine News(10 mins):